Aptose Biosciences Inc. Files 8-K Report
Ticker: APTOF · Form: 8-K · Filed: Dec 19, 2024 · CIK: 882361
Sentiment: neutral
Topics: disclosure, financials, corporate-history
Related Tickers: APTOS
TL;DR
APTOS filed an 8-K on 12/19/24 covering Reg FD and financials. Nothing major revealed yet.
AI Summary
On December 19, 2024, Aptose Biosciences Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc., is incorporated in Canada and has its principal business address in Toronto.
Why It Matters
This 8-K filing provides important updates and disclosures regarding Aptose Biosciences Inc.'s regulatory compliance and financial reporting.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report for disclosures and exhibits, not indicating any immediate material adverse events.
Key Players & Entities
- Aptose Biosciences Inc. (company) — Registrant
- Lorus Therapeutics Inc. (company) — Former Company Name
- Imutec Pharma Inc (company) — Former Company Name
- December 19, 2024 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing for Aptose Biosciences Inc.?
The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on December 19, 2024.
What are some of the former names of Aptose Biosciences Inc. mentioned in the filing?
Former names of Aptose Biosciences Inc. mentioned in the filing include Lorus Therapeutics Inc. and Imutec Pharma Inc.
Where is Aptose Biosciences Inc. incorporated and what is its business address?
Aptose Biosciences Inc. is incorporated in Canada and its business address is 66 Wellington Street West, Suite 5300, TD Bank Tower Box 48, Toronto, ON M5K 1E6.
What is the Standard Industrial Classification code for Aptose Biosciences Inc.?
The Standard Industrial Classification code for Aptose Biosciences Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 506 words · 2 min read · ~2 pages · Grade level 9.7 · Accepted 2024-12-19 16:10:09
Filing Documents
- f8k_121924.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 7KB
- 0001171843-24-007016.txt ( ) — 220KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_121924_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On December 19, 2024, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release dated December 19, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aptose Biosciences Inc. Date: December 19, 2024 By: /s/ William G. Rice, Ph.D. William G. Rice, Ph.D. President and Chief Executive Officer